[Differenciation of reaction mechanisms of alkylating cytostatics on Ehrlich ascites-carcinoma- and lymphatic leucemic cells].
D000477:Alkylating Agents / Q000627:therapeutic use*; D000818:Animals; D002247:Carbon Isotopes; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy* / Q000378:metabolism; D002699:Chlorambucil / Q000627:therapeutic use; D007930:Leucine / Q000378:metabolism; D007942:Leukemia, Experimental / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000378:metabolism; D051379:Mice; D009705:Nucleosides / Q000378:metabolism; D013936:Thymidine / Q000378:metabolism; D014228:Triaziquone / Q000627:therapeutic use; D014529:Uridine / Q000378:metabolism
D000477:Alkylating Agents; D002247:Carbon Isotopes; D009705:Nucleosides; D002699:Chlorambucil; D014228:Triaziquone; D007930:Leucine; D013936:Thymidine; D014529:Uridine
Differenzierung der Wirkungsmechanismen alkylierender Cytostatika an Ehrlich-Ascitescarcinom- und lymphatischen Leukämiezellen.